<DOC>
	<DOC>NCT02686398</DOC>
	<brief_summary>During the 2013-2014 influenza season, CKD patients undergoing HD participated in the study. The patients were randomized into two groups (MF59-adjuvanted vaccine group or non-adjuvanted vaccine group) and were immunized with the respective vaccine. Sera were collected prior to vaccination and at 1and 6 months post vaccination. Levels of hemagglutination inhibition (HI) antibodies were measured.</brief_summary>
	<brief_title>Immunogenicity of a Trivalent Influenza Vaccine in Chronic Kidney Disease Patients Undergoing Hemodialysis</brief_title>
	<detailed_description />
	<mesh_term>Influenza, Human</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure, Chronic</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Chronic kidney disease patients undergoing hemodialysis Who have given written informed consent at the time of enrollment Recipients of influenza vaccine of 20132014 season before the study History of egg allergy</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Influenza Vaccines</keyword>
	<keyword>MF59 oil emulsion</keyword>
	<keyword>End Stage Renal Failure on Dialysis</keyword>
</DOC>